- Home
- SYTA vs QLGN Comparison
SYTA vs QLGN Comparison
Compare SYTA & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYTA
- QLGN
- Stock Information
- Founded
- SYTA N/A
- QLGN 1996
- Country
- SYTA Canada
- QLGN United States
- Employees
- SYTA N/A
- QLGN 4
- Industry
- SYTA Telecommunications Equipment
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- SYTA Telecommunications
- QLGN Health Care
- Exchange
- SYTA Nasdaq
- QLGN Nasdaq
- Market Cap
- SYTA 2.9M
- QLGN 2.7M
- IPO Year
- SYTA 2020
- QLGN N/A
- Fundamental
- Price
- SYTA $1.27
- QLGN $3.60
- Analyst Decision
- SYTA
- QLGN
- Analyst Count
- SYTA 0
- QLGN 0
- Target Price
- SYTA N/A
- QLGN N/A
- AVG Volume (30 Days)
- SYTA 7.4M
- QLGN 226.0K
- Earning Date
- SYTA 11-14-2024
- QLGN 11-29-2024
- Dividend Yield
- SYTA N/A
- QLGN N/A
- EPS Growth
- SYTA N/A
- QLGN N/A
- EPS
- SYTA N/A
- QLGN N/A
- Revenue
- SYTA $11,988,979.00
- QLGN N/A
- Revenue This Year
- SYTA $78.40
- QLGN N/A
- Revenue Next Year
- SYTA $18.06
- QLGN N/A
- P/E Ratio
- SYTA N/A
- QLGN N/A
- Revenue Growth
- SYTA 41.59
- QLGN N/A
- 52 Week Low
- SYTA $0.76
- QLGN $3.55
- 52 Week High
- SYTA $90.90
- QLGN $39.15
- Technical
- Relative Strength Index (RSI)
- SYTA 51.67
- QLGN 25.42
- Support Level
- SYTA $1.17
- QLGN $3.71
- Resistance Level
- SYTA $1.29
- QLGN $4.56
- Average True Range (ATR)
- SYTA 0.14
- QLGN 0.65
- MACD
- SYTA 0.02
- QLGN -0.06
- Stochastic Oscillator
- SYTA 44.19
- QLGN 2.08
About SYTA Siyata Mobile Inc.
Siyata Mobile Inc is engaged in the sale of vehicle mounted, cellular-based communications platforms over advanced 3G (Third generation) mobile networks and cellular booster systems. The Company develops, markets and sells a portfolio of rugged handheld Push-to-Talk over Cellular (PoC) smartphone devices. These rugged business-to-business (B2B) environments are focused on enterprise customers, first responders, construction workers, security guards, government agencies, utilities, transportation and waste management, amusement parks, and mobile workers in multiple industries. The company operates in USA, Canada, EMEA and Australia. It derives maximum revenue from USA.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.